Developing novel therapeutics for Alzheimer's and other neurodegenerative diseases
info@cogrx.com

CogRx Founder and CSO, Dr. Susan Catalano, will co-chair nanosymposium at the Society for Neuroscience 2016 Annual Meeting

Cognition Therapeutics (CogRx) Founder and CSO, Dr. Susan Catalano, will co-chair the nanosymposium titled, “Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics” at the Society for Neuroscience 2016 Annual Meeting in San Diego. The nanosymposium will be held on Wednesday, November 16, 2016 and will be co-chaired by Dr. Bob Mach, Britton Chance Professor of Radiology, Perelman School of Medicine, University of Pennsylvania.

 

Session 765 – Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics

November 16, 2016, 1:00-3:30PM

1:00 – 1:15 PM

765.01 – Sigma-2/PGRMC1 antagonists as disease-modifying therapeutics for Alzheimer’s disease.

*N. J. IZZO, K. MOZZONI, C. SILKY, C. REHAK, R. YURKO, G. LOOK, G. RISHTON, M. GRUNDMAN, H. SAFFERSTEIN, S. M. CATALANO;
Cognition Therapeut. Inc., Pittsburgh, PA

1:15 – 1:30 PM

765.02 – Inhibition of Sig2R/PGRMC : A potential strategy for treating Alzheimer’s disease

*B. YI1, J. J. SAHN2, P. MEMAR ARDESTANI1, A. K. EVANS1, L. SCOTT3, J. Z. CHAN2, J. PIERCE-SHIMOMURA3, S. F. MARTIN2, M. SHAMLOO1;
1Behavioral and Functional Neurosci. Lab., Stanford Univ., Palo Alto, CA; 2Dept. of Chem., 3Ctr. for Learning and Memory, The Univ. of Texas at Austin, Austin, TX

1:30 – 1:45 PM

765.03 – Shedding light on the controversial identity of the sigma-2 receptor with PGRMC1

*M. L. PATI, C. ABATE, M. NISO, F. BERARDI, N. A. COLABUFO;
Dept. di Farmacia-Scienze del Farmaco, Univ. Degli Studi Di Bari, Bari, Italy

1:45 – 2:00 PM

765.04 – On the identity of sigma-2 binding sites and PGRMC1: evidence in neurons relating to Alzheimer’s disease

K. MOZZONI, N. J. IZZO, R. YURKO, C. SILKY, C. REHAK, G. LOOK, G. RISHTON, H. SAFFERSTEIN, *S. M. CATALANO;
Cognition Therapeut. Inc., Pittsburgh, PA

2:00 – 2:15 PM

765.05 – Divergent cytotoxic and metabolically stimulative functions of sigma-2 receptors: Structure-activity relationships in a series of SN79 analogs

H. NICHOLSON1, W. ALSHARIF2, C. R. MCCURDY2, *W. D. BOWEN1;
1Molec Pharmacol, Physiol, & Biotechnol, Brown Univ., Providence, RI; 2Sch. of Pharm., Univ. of Mississippi, University, MS

2:15 – 2:30 PM

765.06 – Targeting Sig2R/PGRMC1 for treating neurological disorders

J. J. SAHN1, T. R. HODGES1, M. D. WOOD1, L. L. SCOTT2, R. C. YEN2, J. PIERCE-SHIMOMURA2, A. A. PIEPER3, T. C. YIN3, T. PRICE4, G. MEJIA4, A. FERRAGUD5, V. SABINO5, P. M. ARDESTANI6, M. SHAMLOO7, *S. MARTIN1;
1Chem., 2Neurosci., Univ. of Texas at Austin, Austin, TX; 3The Univ. of Iowa, Iowa City, IA; 4The Univ. of Texas, Dallas, TX; 5Boston Univ. Sch. of Med., Boston, MA; 6Stanford Behavioral and Functional Neurosci. Lab., 7Neurosurg., Stanford Univ., Stanford, CA

2:30 – 2:45 PM

765.07 – The role of mirna in regulating neuroprotective function of progesterone in ischemic brain

*T. NGUYEN, C. SU, M. SINGH;
Univ. of North Texas Hlth. Sci. Ctr., Fort Worth, TX

2:45 – 3:00 PM

765.08 – Reduction of sigma-2 receptor density in sleep deprived mice

*J. XU1, M. LIM3, D. HOLTZMAN2, R. MACH4;
1Radiology, Washington Univ. Sch. of Med., Saint Louis, MO; 2Washington Univ. Sch. of Med., St. Louis, MO; 3VA Portland Hlth. Care Ctr. and Oregon Hlth. & Sci. Univ., Portland, OR; 4Univ. of Pennsylvania, Philadelphia, PA

3:00 – 3:15 PM

765.09 – The sigma-2 receptor has different but overlapping binding sites for small molecules as measured by radioligand binding studies

*R. H. MACH, B. P. LIEBERMAN;
Radiology, Univ. of Pennsylvania, Philadelphia, PA

3:15 – 3:30 PM

765.10 – PGRMC1/sigma-2 receptor: A novel carbon monoxide sensor to regulate cell function

*M. SUEMATSU, Y. KABE;
Biochem., Keio Univ. Sch. of Med., Tokyo, Japan